Association Between Retinal Vein Occlusion and Epiretinal Membrane Development - 05/05/26
Highlights |
• | Peak epiretinal membrane (ERM) formation occurs within the first 3 months in patients with retinal vein occlusion (RVO). |
• | Peak membrane peeling occurs about one year after ERM formation in patients with RVO. |
• | Anti-VEGF treatment is linked to higher ERM formation in patients with RVO. |
• | Anti-VEGF treated eyes with RVO show delayed timing of ERM peeling. |
Résumé |
Purpose |
To evaluate the temporal association between retinal vein occlusion (RVO) and the development of epiretinal membrane (ERM) including subsequent ERM peel.
Design |
Retrospective cohort study.
Participants |
After propensity score matching (PSM) and applying inclusion/exclusion criteria, 19,172 patients with branch retinal vein occlusion (BRVO) and 14,974 with central retinal vein occlusion (CRVO) were compared with matched controls.
Methods |
Data was extracted using a national clinical database. Patients with BRVO or CRVO were compared with individuals without RVO (control) for the development of main outcomes measures. Secondary analyses examined RVO cohorts with anti-VEGF injections: BRVO-T (anti-VEGF–treated) and CRVO-T versus their respective untreated counterparts. Main Outcome Measures: Relative risk (RR) of incident ERM formation and ERM peel at multiple time points from 3 months to 5 years.
Results |
During the 5-year study period, BRVO and CRVO cohorts had the highest risk for ERM formation at 3 months compared with their respective controls (BRVO: RR = 4.54; CRVO: RR = 4.90; P < .0001). The risk of ERM peel was greatest at one year for BRVO (RR, 3.83; P < .0001) and 3 years for CRVO (RR, 3.91; P < .0001). In the secondary analysis, anti-VEGF treatment was associated with higher ERM rates at 3 months in BRVO-T (RR, 5.60; P < .0001) and CRVO-T (RR, 6.80; P < .0001) cohorts. The incidence of ERM peel peaked later in treated eyes at 5 years (BRVO-T: RR, 3.30; P = .0004; CRVO-T: RR, 2.60; P = .0075) compared with untreated eyes.
Conclusions |
ERM formation typically occurs during the first 3 months following RVO, while surgical intervention peaks later, as early as one year in untreated eyes, and 5 years in eyes treated with anti-VEGF agents. Treated patients also exhibited an elevated risk for ERM development, which could be influenced by differences in baseline disease severity rather than a clear treatment effect.
Le texte complet de cet article est disponible en PDF.Abbreviations : ERM, ILM, RVO, BRVO, CRVO, BRVO-R, BRVO-L, CRVO-R, CRVO-L, VEGF, BRVO-T, CRVO-T, DR, PDR, NPDR, CPT, ICD-10, PVD, PSM, RR, RD, CI, SD, US, STROBE, OR
Plan
Vol 286
P. 108-122 - juin 2026 Retour au numéro
Article précédent
- Assessing the Fragility of Statistically Significant Outcomes in Randomized Controlled Trials of Minimally Invasive Glaucoma Surgery (MIGS)
- Abdus Samad Ansari, Minsu Jung, Amar Hamdan, Amrit Hayre, Jeremy Tan, Daniyal Matin Ansari, Peng T. Khaw, Gus Gazzard
- Effects of Optic Nerve Head Structures on Retinal Nerve Fiber Layer Defects in Primary Open Angle Glaucoma Eyes: Analyses Using Retinal Optical Texture Analysis
- Atsuya Miki, Makoto Araie, Christopher Kai Shun Leung, Masashi Nishigaki, Hiroshi Murata, Tsutomu Kikawa, Kazuhisa Sugiyama, Tomomi Higashide, Hitomi Saito, Makoto Aihara, Aiko Iwase, Goji Tomita, Toru Nakazawa, Kyoko Ohno-Matsui, Tae-Woo Kim, Linda M. Zangwill, Robert N. Weinreb
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?